Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). There are currently no effective FTLD therapies, although new drugs are reaching the stage where clinical trials are warranted. The overarching goal of this proposal is to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD therapies. The FTLD CRC will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Patients will be evaluated at 13 clinical sites throughout North America, and a genetics core will genotype all individuals for FTLD associated genes. Clinical research projects will focus on specific FTLD syndromes where there is a strong correlation between clinical syndrome and underlying pathology, who are targeted for enrollment in new trials. Research Project 1 will collect cross-sectional data in sporadic FTLD patients using a new FTLD assessment battery, as well as screening all individuals for known FTLD-causing mutations and evidence of systemic inflammation, to prepare for trials of anti-tau and anti-inflammatory agents. Research Project 2 will collect longitudinal clinical and MRl data on familial FTLD (f-FTLD) individuals who carry mutations in MAPT, GRN and C90RF72 and their asymptomatic family members to enable disease prevention clinical trials.
Our specific aims are to: 1) build a FTLD clinical trials network to facilitate the design and conduct of clinical trials;2) determine the clinical, genetic and systemic inflammatory cytokine profile of sporadic FTLD targeted for new trials: semantic variant PPA, FTD with amyotrophic lateral sclerosis and PSPS;3) determine the natural history of asymptomatic and symptomatic f-FTLD patients using novel clinical measures and MR imaging over one year;4) obtain pilot data using the new tau PET imaging agent PBB3 in FTLD, and other novel FTLD biomarkers and clinical tools that may be employed in future trials;5) train clinical researchers focused on FTLD therapeutic development.

Public Health Relevance

Frontotemporal Lobar Degeneration (FTLD) is a group of rare, fatal brain diseases that cause thinking and movement problems and for which there are currently no effective therapies. This project will build a North American clinical research network to prepare for studies of new FTLD treatments. Developing FTLD therapies may also help to find a cure for more common disorders such as Alzheimer's disease.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel ()
Program Officer
Sutherland, Margaret L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Cooper, Yonatan A; Nachun, Daniel; Dokuru, Deepika et al. (2018) Progranulin levels in blood in Alzheimer's disease and mild cognitive impairment. Ann Clin Transl Neurol 5:616-629
Finger, Elizabeth; Berry, Scott; Cummings, Jeffrey et al. (2018) Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). Alzheimers Res Ther 10:102
Björkhem, Ingemar; Patra, Kalicharan; Boxer, Adam L et al. (2018) 24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome. Front Neurol 9:756
Chen, Jason A; Chen, Zhongbo; Won, Hyejung et al. (2018) Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Mol Neurodegener 13:41
Jones, David T; Knopman, David S; Graff-Radford, Jonathan et al. (2018) In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90:e947-e954
Casaletto, K B; Elahi, F M; Fitch, R et al. (2018) A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? Cytokine 111:481-489
Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858
Ljubenkov, Peter A; Staffaroni, Adam M; Rojas, Julio C et al. (2018) Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol 5:1250-1263
La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290
Iaccarino, Leonardo; Tammewar, Gautam; Ayakta, Nagehan et al. (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin 17:452-464

Showing the most recent 10 out of 92 publications